Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma

There are only limited treatment options for metastatic NRAS mutant melanoma patients with resistance to immune checkpoint inhibitors. Besides activation of the mitogen-activated protein (MAP) kinase pathway, they often have additional disturbances in cell cycle regulation. However, unlike BRAF muta...

Full description

Bibliographic Details
Main Authors: Andrea Forschner, Tobias Sinnberg, Gabi Mroz, Christopher Schroeder, Christian Philipp Reinert, Sergios Gatidis, Michael Bitzer, Thomas Eigentler, Claus Garbe, Heike Niessner, Martin Röcken, Cristiana Roggia, Sorin Armeanu-Ebinger, Olaf Riess, Sven Mattern, Dominik Nann, Irina Bonzheim
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
melanoma
CDKN2A
NRAS
ribociclib
binimetinib
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.643156/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.643156/full

Similar Items